Compass Therapeutics (NASDAQ:CMPX) Stock Rating Upgraded by LADENBURG THALM/SH SH

Compass Therapeutics (NASDAQ:CMPX) was upgraded by analysts at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage presently has a $5.00 price objective on the stock. LADENBURG THALM/SH SH’s target price would indicate a potential upside of 201.20% from the stock’s previous close.

Several other research analysts also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research report on Monday, August 12th. Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $1.66 on Monday. The company’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $1.42. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34. The company has a market capitalization of $228.40 million, a P/E ratio of -4.61 and a beta of 0.88.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Monday, August 12th. The company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). The business had revenue of $0.85 million during the quarter. On average, analysts anticipate that Compass Therapeutics will post -0.42 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Element Capital Management LLC acquired a new stake in shares of Compass Therapeutics during the 4th quarter valued at $458,000. Pale Fire Capital SE boosted its position in Compass Therapeutics by 301.0% during the fourth quarter. Pale Fire Capital SE now owns 181,055 shares of the company’s stock valued at $282,000 after purchasing an additional 135,900 shares during the last quarter. Pennant Investors LP acquired a new stake in Compass Therapeutics during the fourth quarter valued at $310,000. Simplicity Wealth LLC purchased a new position in Compass Therapeutics in the first quarter valued at about $80,000. Finally, Bleakley Financial Group LLC acquired a new position in Compass Therapeutics in the 1st quarter worth about $80,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.